Affiliation:
1. Federal Research Centre of Nutrition, Biotechnology and Food Safety
2. Federal Research Centre of Nutrition, Biotechnology and Food Safety; Russian Medical Academy of Continuing Professional Education; I. M. Sechenov First Moscow State Medical University of Ministry of Healthcare of the Russian Federation (Sechenov University)
Abstract
Аim: to analyze and summarize literature data on the effect of peroxisome proliferator-activated receptors (PPARs) on cardiometabolic parameters in chronic non-infectious diseases, including type 2 diabetes mellitus.Materials and methods: a comprehensive search was conducted in electronic databases, including PubMed/Medline, Web of Science, Scopus, on the role of peroxisome proliferator-activated receptors (PPAR) on cardiometabolic parameters in type 2 diabetes mellitus.Results: the relevance of research into the identification of structural determinants responsible for the binding and activation of PPAR is shown. Their contributions are particularly relevant in the characterization and optimization of new PPAR modulators of different origins, taking into account their activity, selectivity and safety profiles. Identification of known PPAR agonists found in foods makes a potential contribution to the comprehensive treatment of patients with type 2 diabetes. PPAR receptors play a key role in lipid metabolism and glucose homeostasis, as well as in the prevention and treatment of metabolic diseases.Conclusion: further research on the role of PPAR agonists of various isoforms opens up new perspectives with the use of dietary and drug therapies in a number of metabolic diseases.
Reference27 articles.
1. Drapkina O. M., Kontsevaya A. V., Kalinina A. M., Avdeev S. N., Agaltsov M. V., Alexandrova L. M. et al. Prevention of chronic non-communicable diseases in the Russian Federation. National guidelines. Cardiovascular Therapy and Prevention. 2022; 21 (4): 3235. (In Russ.). DOI: 10.15829/1728–8800–2022–3235. EDN DNBVAT.
2. Clinical recommendations. Algorithms of specialized medical care for patients with diabetes mellitus. Ed. I. I. Dedova, M. V. Shestakova, A. Yu. Mayorova. – 10th edition (updated). M., 2021. (In Russ.). DOI: 10:14341/DM12802
3. Valeeva F. V., Medvedeva M. S., Khasanova K. B., Valeeva E. V., Kiseleva T. A., Egorova E. S., Pickering C., Ahmetov I. I. Association of gene polymorphisms with body weight changes in prediabetic patients. Mol Biol Rep. 2022 Jun; 49 (6): 4217–4224. DOI: 10.1007/s11033-022-07254-y
4. Bougarne N., Weyers B., Desmet S. J., Deckers J., Ray D. W., Staels B., De Bosscher K. Molecular Actions of PPARα in Lipid Metabolism and Inflammation. Endocr Rev. 2018 Oct 1; 39 (5): 760–802. DOI: 10.1210/er.2018-00064
5. Lin Y., Wang Y., Li P. F.PPARα: An emerging target of metabolic syndrome, neurodegenerative and cardiovascular diseases. Front Endocrinol (Lausanne). 2022 Dec 16; 13: 1074911. DOI: 10.3389/fendo.2022.1074911